LA JOLLA, Calif., Feb. 12, 2015 /PRNewswire/ -- Regulus
Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company
leading the discovery and development of innovative medicines
targeting microRNAs, today announced that it will report financial
results and highlights for the fourth quarter and year ended
December 31, 2014 on Wednesday, February 18, 2015, after the U.S.
financial markets close.
![Regulus Therapeutics Inc. Logo Regulus Therapeutics Inc. Logo](http://photos.prnewswire.com/prnvar/20150130/172637LOGO)
Regulus will host a conference call and webcast on Wednesday, February 18, 2015, at 5:00 pm Eastern Standard Time to discuss its
fourth quarter and year-end 2014 financial results and recent
company highlights. A live webcast of the call will be available
online at www.regulusrx.com. To access the call, please dial
(877) 257-8599 (domestic) or (970) 315-0459 (international) and
refer to conference ID 87438466. To access the telephone
replay of the call, dial (855) 859-2056 (domestic) or (404)
537-3406 (international), passcode 87438466. The webcast and
telephone replay will be archived on the company's website
following the call.
About Regulus
Regulus Therapeutics Inc. (NASDAQ:RGLS) is a
biopharmaceutical company leading the discovery and development of
innovative medicines targeting microRNAs. Regulus has
leveraged its oligonucleotide drug discovery and development
expertise to develop a well-balanced microRNA therapeutics pipeline
complemented by a maturing microMarkersSM biomarkers
platform and a rich intellectual property estate to retain its
domain dominant leadership in the microRNA field. Under its
'Clinical Map Initiative', Regulus is developing RG-101, a
GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment
of chronic hepatitis C virus infection, and RG-012, an anti-miR
targeting microRNA-21 for the treatment of Alport syndrome, a
life-threatening kidney disease driven by genetic mutations with no
approved therapy. Regulus is also advancing several programs toward
clinical development in orphan disease indications, oncology and
fibrosis. Regulus' commitment to innovation has resulted in
multiple peer-reviewed publications in notable scientific journals
and has resulted in the formation of strategic alliances with
AstraZeneca and Sanofi and a research collaboration with Biogen
Idec focused on microRNA biomarkers. Regulus maintains its
corporate headquarters in La Jolla,
CA. For more information, please
visit http://www.regulusrx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with Regulus' expectations
regarding future therapeutic and commercial potential of Regulus'
business plans, technologies and intellectual property related to
microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. These and other risks
concerning Regulus' programs are described in additional detail in
Regulus' SEC filings. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Logo - http://photos.prnewswire.com/prnh/20150130/172637LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/regulus-announces-timing-for-fourth-quarter-and-year-end-2014-financial-results-webcast-and-conference-call-300035541.html
SOURCE Regulus Therapeutics Inc.